2. Induced Disease Models Products Cell Cycle/DNA Damage Antibody-drug Conjugate/ADC Related PI3K/Akt/mTOR Epigenetics Autophagy Apoptosis Anti-infection
  3. Cardiovascular System Disease Models Topoisomerase ADC Cytotoxin AMPK Autophagy Apoptosis HIV HBV Mitophagy Antibiotic Bacterial
  4. Heart Disease Models
  5. Doxorubicin hydrochloride

Doxorubicin hydrochloride  (Synonyms: Hydroxydaunorubicin hydrochloride)

Cat. No.: HY-15142 Purity: 99.60%
COA Handling Instructions

Chlorhydrate de doxorubicine (chlorhydrate d'hydroxydaunorubicine), un antibiotique anthracycline cytotoxique, est un agent de chimiothérapie anticancéreuse. Chlorhydrate de doxorubicine inhibe la topoisomérase, arrêtant ainsi la réplication de l'ADN. Chlorhydrate de doxorubicine réduit la phosphorylation basale de AMPK et de son cible en aval acétyl-CoA carboxylase. Chlorhydrate de doxorubicine induit l'apoptose et l'autophagie.

Doxorubicin hydrochloride (Hydroxydaunorubicin hydrochloride), ein zytotoxisches Anthracyclin-Antibiotikum, ist ein Chemotherapeutikum gegen Krebs. Doxorubicinhydrochlorid hemmt die topoisomerase II und stoppt so die DNA-Replikation. Doxorubicin-Hydrochlorid reduziert die basale Phosphorylierung von AMPK und seiner nachgeschalteten Ziel-Acetyl-CoA-Carboxylase. Doxorubicinhydrochlorid induziert apoptosis und autophagy.

Doxorubicin (Hydroxydaunorubicin) hydrochloride, a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC50s of 0.8 μM and 2.67 μM, respectively. Doxorubicin hydrochloride reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin hydrochloride induces apoptosis and autophagy.

For research use only. We do not sell to patients.

Doxorubicin hydrochloride Chemical Structure

Doxorubicin hydrochloride Chemical Structure

CAS No. : 25316-40-9

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solution
10 mM * 1 mL in DMSO USD 66 In-stock
Solid + Solvent
10 mM * 1 mL
ready for reconstitution
 USD 66 In-stock
Solid
50 mg USD 60 In-stock
100 mg USD 84 In-stock
200 mg USD 144 In-stock
500 mg USD 264 In-stock
1 g USD 474 In-stock
5 g   Get quote  
10 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 329 publication(s) in Google Scholar

Other Forms of Doxorubicin hydrochloride:

Doxorubicin hydrochloride Related Antibodies

Top Publications Citing Use of Products

318 Publications Citing Use of MCE Doxorubicin hydrochloride

IF
WB
IHC

    Doxorubicin hydrochloride purchased from MCE. Usage Cited in: Cell Death Dis. 2019 Nov 25;10(12):887.  [Abstract]

    Doxorubicin or CPT-11 significantly promoted KRT8 expression in chordoma cells in vitro. Western blotting analysis and quantification of KRT8 protein expression (normalized to GAPDH expression).

    Doxorubicin hydrochloride purchased from MCE. Usage Cited in: Cell Death Dis. 2019 Nov 25;10(12):887.  [Abstract]

    Doxorubicin or CPT-11 significantly promoted KRT8 expression in chordoma cells in vitro. Representative images of immunofluorescence staining of KRT8 of CM318 and UCH1 cell line.

    Doxorubicin hydrochloride purchased from MCE. Usage Cited in: Free Radic Biol Med. 2019 Jan;130:557-567.  [Abstract]

    Representative pictures of Live/Dead staining of effects of 7,8-DHF on high dose of Dox-induced cell death and MMP reduction of H9c2 cells.

    Doxorubicin hydrochloride purchased from MCE. Usage Cited in: J Cell Mol Med. 2019 Sep;23(9):6034-6047.  [Abstract]

    Effects of YWPC (50 mg/L for 24 h) on DOX (5 μM for 24 h)-induces dissipation of mitochondrial membrane potential measured in H9C2 cells loaded with JC-1 using fluorescence microscopy.

    Doxorubicin hydrochloride purchased from MCE. Usage Cited in: Nat Commun. 2018 Oct 8;9(1):4139.  [Abstract]

    One hour after treated with UV or 2 h after treated with MMS, Camptothecin (CPT) (10 μM), or Doxorubicin (DOX; 0.5 μM), HEK293T cells expressing HA-SUMO2 and His-RhoB are subjected to sumoylation assay to detect the SUMO2 conjugation of RhoB.

    Doxorubicin hydrochloride purchased from MCE. Usage Cited in: J Clin Invest. 2018 Jan 2;128(1):483-499.  [Abstract]

    Immunoblotting for EZH2 in lysates of immortalized mouse podocytes after treatment with Adriamycin (300 ng/mL) for 48 hours (n=6).

    Doxorubicin hydrochloride purchased from MCE. Usage Cited in: J Exp Clin Cancer Res. 2018 Sep 19;37(1):232.  [Abstract]

    Immunoblotting shows that both P-gp protein expression is significantly decreased in 24 h after US exposure in MCF-7/ADR and HEPG2/ADM cells.

    Doxorubicin hydrochloride purchased from MCE. Usage Cited in: Nanoscale Res Lett. 2018 Nov 3;13(1):350.  [Abstract]

    HY-15142

    Doxorubicin hydrochloride purchased from MCE. Usage Cited in: Cell Signal. 2017 May 1;36:108-116.  [Abstract]

    PAQR3 affects DNA damage repair. AGS cells are treated with different doses of VP-16 (for 24 h), CDDP (for 24 h) and Doxorubicin (for 10 h) as indicated, followed by immunoblotting with the antibodies.

    Doxorubicin hydrochloride purchased from MCE. Usage Cited in: Cell Physiol Biochem. 2017;42(3):965-973.  [Abstract]

    U937 cells are treated with Thapsigargin (TG, 1 μM), NSC 125973 (PTX, 5nM) as well as Doxorubincin (DOX, 1 μM) for 12 hours and the indicated proteins are detected by Western blot.

    Doxorubicin hydrochloride purchased from MCE. Usage Cited in: Nat Med. 2016 May;22(5):547-56.  [Abstract]

    Immunofluorescent staining for α-actinin (ACTN2) and cardiac troponin T (TNNT2) to demonstrate sarcomeric organization in hiPSC–CMs derived from patients who do not experience Doxorubicin–induced cardiotoxicity (DOX) versus those who do experience Doxorubicin-induced cardiotoxicity (DOXTOX) after 24 h treatment with Doxorubicin. Scale bar, 20 µm.

    View All Topoisomerase Isoform Specific Products:

    View All Isoforms
    Topoisomerase Topo I Topo II

    View All ADC Cytotoxin Isoform Specific Products:

    View All Isoforms
    Auristatin Calicheamicins Camptothecins Daunorubicins/Doxorubicins Duocarmycins Maytansinoids Pyrrolobenzodiazepines Traditional Cytotoxic Agents

    View All AMPK Isoform Specific Products:

    View All Isoforms
    NUAK1 NUAK2 AMPK AMPK α1β1γ1 AMPK α2β1γ1 AMPK α1β2γ1 AMPK α2β2γ1

    View All Antibiotic Isoform Specific Products:

    View All Isoforms
    Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Doxorubicin (Hydroxydaunorubicin) hydrochloride, a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC50s of 0.8 μM and 2.67 μM, respectively. Doxorubicin hydrochloride reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin hydrochloride induces apoptosis and autophagy[1][2][3].

    IC50 & Target[1][2][3]

    Topoisomerase I

    0.8 μM (IC50)

    Topoisomerase II

    2.67 μM (IC50)

    Daunorubicins/Doxorubicins

     

    HIV-1

     

    In Vitro

    Doxorubicin hydrochloride (1-8 μM; 24 and 48 hours) decreases the viability of MCF-10F, MCF-7 and MDA-MB-231 cells in a time- and dose-dependent manner[4].
    Doxorubicin hydrochloride (1 μM; 3 and 24 hours) results in Hct-116 human colon carcinoma cells reduction in G0/G1 phase and accumulation in G2 phase[5].
    Doxorubicin hydrochloride (1 μM for MCF-10F and MDA-MB-231 cells, 4 μM for MCF-7 cells; 48 hours) induces apoptosis by upregulating Bax, caspase-8 and caspase-3 and downregulation of Bcl-2 protein expression[4].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Doxorubicin hydrochloride Related Antibodies

    Cell Viability Assay[4]

    Cell Line: Breast cancer cell lines MCF-10F, MCF-7 and MDA-MB-231
    Concentration: 0, 1, 2, 4 and 8 μM
    Incubation Time: 24 and 48 hours
    Result: IC50 was 1 μM for both MCF-10F and MDA-MB-231 cell lines.
    IC50 was 4 μM for MCF-7 cell line.

    Cell Cycle Analysis[5]

    Cell Line: Hct-116 human colon carcinoma cells
    Concentration: 1 μM
    Incubation Time: 3 hours and 24 hours
    Result: Both, bolus (3 h) and continuous (24 h) incubation led to a significant reduction of cells in G0/G1 and accumulation in G2 phase.

    Western Blot Analysis[4]

    Cell Line: Breast cancer cell lines MCF-10F, MCF-7 and MDA-MB-231
    Concentration: 1 μM for MCF-10F and MDA-MB-231 cells, 4 μM for MCF-7 cells
    Incubation Time: 48 hours
    Result: Bax protein expression was upregulated in MCF-10F and MDA-MB-231 cell lines but MCF-7 cells did not show any significant increase.
    Caspase-8 gene expression was upregulated in MCF-10F, but it was downregulated in MCF-7 and MDA-MB-231 cells.
    In Vivo

    Doxorubicin hydrochloride can be used in animal modeling to construct animal heart failure models.

    Treatment with Doxorubicin (2 mg/kg) or Zoledronic acid (100 μg/kg) alone does not statistically significantly decrease final tumor volume compared with saline. Mice treated with Doxorubicin plus Zoledronic acid have statistically significantly smaller final tumor volumes than those treated with Doxorubicin alone[6].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Female MF1 nu/nu mice bearing MDA-G8 breast tumor xenograft (6-week-old)[6]
    Dosage: Doxorubicin (2 mg/kg); Zoledronic acid (100 μg/kg)
    Administration: Intravenous injection; once a week; 6 weeks
    Result: Moderate inhibition of subcutaneous tumor growth in mice that were treated with 2 mg/kg Doxorubicin alone or with 100 μg/kg Zoledronic acid alone compared to the saline control.
    Mice treated with Zoledronic acid and Doxorubicin together had statistically significant smaller mean tumor volumes on day 42 than those treated with Doxorubicin alone.
    Clinical Trial
    Molecular Weight

    579.98

    Appearance

    Solid

    Formula

    C27H30ClNO11
    CAS No.
    SMILES

    COC1=C2C(C(C(C(O)=C(C[C@](C(CO)=O)(O)C[C@@H]3O[C@@]4([H])C[C@H](N)[C@H](O)[C@H](C)O4)C3=C5O)=C5C2=O)=O)=CC=C1.[H]Cl
    Structure Classification
    Initial Source

    Streptomyces peucetius var. Caesius
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage

    4°C, sealed storage, away from moisture and light

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

    Solvent & Solubility
    In Vitro: 

    DMSO : 35.71 mg/mL (61.57 mM; ultrasonic and warming and heat to 60°C)

    H2O : 20 mg/mL (34.48 mM; Need ultrasonic)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.7242 mL 8.6210 mL 17.2420 mL
    5 mM 0.3448 mL 1.7242 mL 3.4484 mL
    10 mM 0.1724 mL 0.8621 mL 1.7242 mL
    *Please refer to the solubility information to select the appropriate solvent.
    In Vivo:
    • 1.

      Add each solvent one by one:  5% DMSO    40% PEG300    5% Tween-80    50% saline

      Solubility: ≥ 2.75 mg/mL (4.74 mM); Clear solution

    • 2.

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

      Solubility: ≥ 2.08 mg/mL (3.59 mM); Clear solution

    • 3.

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in saline)

      Solubility: ≥ 2.08 mg/mL (3.59 mM); Clear solution

    *All of the co-solvents are available by MCE.
    Purity & Documentation

    Purity: 99.60%

    COA (258 KB) HNMR (284 KB) RP-HPLC (213 KB) LCMS (117 KB)

    Handling Instructions (2659 KB)
    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Doxorubicin hydrochloride Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2

    Keywords:

    Doxorubicin25316-40-9HydroxydaunorubicinTopoisomeraseADC CytotoxinAMPKAutophagyApoptosisHIVHBVMitophagyAntibioticBacterialADC PayloadAMP-activated protein kinaseHuman immunodeficiency virusHepatitis B virusMitochondrial AutophagyInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Salutation

    Applicant Name *

    		 

    Email Address *

    Phone Number *

    		 

    Organization Name *

    Department *

    		 

    Requested quantity *

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Doxorubicin hydrochloride
    Cat. No.:
    HY-15142
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.